Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). This page aggregates official press releases and verified news about the company’s clinical developments, research breakthroughs, and strategic partnerships.
Investors and industry professionals will find timely updates on ALGS’ pipeline candidates including oral capsid assembly modulators targeting viral suppression in CHB and THR-β agonists addressing liver fat reduction in MASH. The curated news collection provides essential context for understanding clinical trial progress, regulatory milestones, and scientific advancements.
Key content categories include updates on: Phase 1-3 clinical trials, collaborative research initiatives, regulatory communications, and therapeutic mechanism insights. All information is sourced from official company disclosures and reputable industry publications.
Bookmark this page for structured access to ALGS’ evolving scientific narrative. Check regularly for developments in oligonucleotide-based therapies and small molecule candidates progressing through clinical evaluation.
Aligos Therapeutics (Nasdaq: ALGS), a clinical-stage biopharmaceutical company, announced that six of its abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2024, taking place from June 5-8 in Milan, Italy. The accepted abstracts include findings on their novel therapeutics for liver and viral diseases.
Highlighted abstracts involve the Capsid Assembly Modulator (CAM) ALG-000184, which has shown promising antiviral effects in chronic hepatitis B (CHB) patients. Notably, two abstracts have earned 'Top' recognition for their outstanding contribution: one on second-generation HBV siRNAs demonstrating improved profiles, and another on CAM-A molecules inducing rapid HBsAg reductions in animal models.
The presentations cover both preclinical and clinical research, reflecting Aligos' leadership in addressing unmet medical needs in liver diseases.
Aligos Therapeutics (Nasdaq: ALGS) has completed enrollment for its Phase 2a HERALD study of ALG-055009, targeting metabolic dysfunction-associated steatohepatitis (MASH). The study enrolled around 100 subjects with liver fibrosis. Topline safety and efficacy data are expected in early Q4 2024.
Dr. Rohit Loomba, a renowned expert in gastroenterology and hepatology, will serve as the Principal Investigator. The trial involves a double-blind, placebo-controlled design with subjects receiving one of four doses or placebo for 12 weeks. The primary endpoint is the relative change in liver fat content measured by MRI-PDFF.
The study aims to assess safety, pharmacokinetics, and other non-invasive biomarkers influenced by thyroid hormone receptor beta agonists. The completion of enrollment is a significant milestone for Aligos.
Aligos Therapeutics, a clinical stage biopharmaceutical company, reported recent business progress and financial results for the first quarter of 2024. They initiated the Phase 2a HERALD study of their drug candidate ALG-055009 and presented positive data on their other programs at scientific conferences. The company's cash balance remains strong to fund operations until the end of 2025.
Aligos Therapeutics, a clinical stage biopharmaceutical company, will announce its 1st Quarter 2024 financial results on May 7, 2024. The company focuses on developing therapeutics for liver and viral diseases.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
